York PA 乳腺癌临床试验
8项针对 乳腺癌的研究正在 York及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- WellSpan York Cancer Center, York
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- Cancer Care Associates Of York ( Site 0063), York
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Cancer Care Associates of York, Inc., York
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- WellSpan Health - York Cancer Center, York
CtDNA Based MRD Testing for NAC Monitoring in TNBC
招募中观察性研究
- Cancer Care Associates of York, York
其他城市的 乳腺癌试验
- New York City, NY136 项研究
- Houston, TX126 项研究
- Boston, MA112 项研究
- Nashville, TN81 项研究
- Los Angeles, CA73 项研究
- Edison, NJ68 项研究
- St. Louis, MO64 项研究
- Queens, NY64 项研究
- Durham, NC64 项研究
- Chicago, IL59 项研究
- Philadelphia, PA56 项研究
- Dallas, TX55 项研究
York的其他研究
- 非小细胞肺癌15 项研究
- 癌症（所有类型）8 项研究
- 肺癌8 项研究
- 头颈鳞状细胞癌7 项研究
- 卵巢癌6 项研究
- 前列腺癌5 项研究
- 冠状动脉疾病5 项研究
- 食管癌4 项研究
- 三阴性乳腺癌4 项研究
- 结直肠癌4 项研究
- 子宫内膜癌4 项研究
- 结肠癌3 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。